These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 18026875)

  • 1. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
    Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
    Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling.
    Wasielewski M; Nagel JH; Brekelmans C; Klijn JG; van den Ouweland A; Meijers-Heijboer H; Schutte M
    Breast Cancer Res Treat; 2007 Aug; 104(2):153-7. PubMed ID: 17080308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations.
    Nechushtan H; Hamburger T; Mendelson S; Kadouri L; Sharon N; Pikarsky E; Peretz T
    BMC Cancer; 2009 Feb; 9():60. PubMed ID: 19226467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.
    Levy-Lahad E; Lahad A; Eisenberg S; Dagan E; Paperna T; Kasinetz L; Catane R; Kaufman B; Beller U; Renbaum P; Gershoni-Baruch R
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3232-6. PubMed ID: 11248061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
    Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
    Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
    Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
    Mol Carcinog; 2010 Jun; 49(6):545-55. PubMed ID: 20306497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
    Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
    Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
    Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.
    Campbell IG; Eccles DM; Choong DY
    Cancer Lett; 2006 Aug; 240(2):195-7. PubMed ID: 16239061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.
    Copson ER; White HE; Blaydes JP; Robinson DO; Johnson PW; Eccles DM
    BMC Cancer; 2006 Mar; 6():80. PubMed ID: 16563154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
    Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
    Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
    Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
    Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
    Barnes-Kedar I; Bernstein-Molho R; Ginzach N; Hartmajer S; Shapira T; Magal N; Kalis ML; Peretz T; Shohat M; Basel-Salmon L; Friedman E; Bazak L; Goldberg Y
    Breast Cancer Res Treat; 2018 Nov; 172(1):151-157. PubMed ID: 30014164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
    Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
    Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.
    Bjørnslett M; Knappskog S; Lønning PE; Dørum A
    BMC Cancer; 2012 Oct; 12():454. PubMed ID: 23039163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.
    Berman DB; Costalas J; Schultz DC; Grana G; Daly M; Godwin AK
    Cancer Res; 1996 Aug; 56(15):3409-14. PubMed ID: 8758903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
    Neuhausen S; Gilewski T; Norton L; Tran T; McGuire P; Swensen J; Hampel H; Borgen P; Brown K; Skolnick M; Shattuck-Eidens D; Jhanwar S; Goldgar D; Offit K
    Nat Genet; 1996 May; 13(1):126-8. PubMed ID: 8673092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.